Lexston Life Sciences Corp. (TSE:LEXT)
:LEXT
Top Page
Lexston Life Sciences Corp.
(LEXT)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.06
▼(-38.00% Downside)
Action:ReiteratedDate:04/08/26
The score is driven primarily by weak financial performance (zero recent revenue, persistent losses, and ongoing cash burn), partially offset by the absence of debt. Technicals add downside risk with a clear bearish trend below key moving averages and negative MACD, while valuation is difficult to support given negative earnings and no dividend yield.
Positive Factors
Low leverage / no reported debt
A zero-debt capital structure materially reduces solvency and interest burdens, preserving strategic optionality. Over several months this provides durable flexibility to fund restructuring, R&D or commercialization via equity or partnerships rather than servicing debt, lowering bankruptcy risk.
Negative Factors
Zero recent revenue
Sustained absence of revenue is a structural weakness: without sales the firm cannot self-fund operations or prove market demand. Over a multi-month horizon this erodes competitive position, hampers customer retention, and forces reliance on external financing or asset monetization.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / no reported debt
A zero-debt capital structure materially reduces solvency and interest burdens, preserving strategic optionality. Over several months this provides durable flexibility to fund restructuring, R&D or commercialization via equity or partnerships rather than servicing debt, lowering bankruptcy risk.
Read all positive factors
Lexston Life Sciences Corp. (LEXT) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$1.76M
Dividend YieldN/A
Average Volume (3M)40.70K
Price to Earnings (P/E)―
Beta (1Y)-0.16
Revenue GrowthN/A
EPS Growth28.37%
CountryCA
EmployeesN/A
SectorBasic Materials
Sector Strength58
IndustryIndustrial Materials
Share Statistics
EPS (TTM)-0.02
Shares Outstanding25,093,304
10 Day Avg. Volume77,591
30 Day Avg. Volume40,703
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)13.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lexston Life Sciences Corp. Business Overview & Revenue Model
Company Description
Lexston Life Sciences Corp. operates as a biotechnology company that provides cannabis testing and research services in Canada. The company also offers analytical testing for cannabis, pathogens, and toxins. In addition, it focuses on developing a...
Lexston Life Sciences Corp. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Aug 2025 | Aug 2024 | May 2023 | Aug 2022 | Aug 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 361.01K | 149.11K |
| Gross Profit | 0.00 | 0.00 | -26.39K | -29.80K | 241.49K | 60.10K |
| EBITDA | -1.45M | -1.54M | -648.32K | -841.73K | -2.29M | -479.82K |
| Net Income | -1.53M | -1.62M | -867.71K | -1.11M | -2.32M | -876.13K |
Balance Sheet | ||||||
| Total Assets | 1.16M | 279.49K | 750.95K | 814.30K | 952.80K | 1.10M |
| Cash, Cash Equivalents and Short-Term Investments | 278.52K | 2.32K | 390.40K | 511.00K | 590.49K | 949.17K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 130.55K | 208.82K | 39.87K | 11.21K | 79.09K | 38.81K |
| Stockholders Equity | 1.02M | 70.67K | 711.08K | 803.10K | 873.71K | 1.06M |
Cash Flow | ||||||
| Free Cash Flow | -1.02M | -1.19M | -723.16K | -987.74K | -1.40M | -608.63K |
| Operating Cash Flow | -1.02M | -1.19M | -523.18K | -987.74K | -1.40M | -483.16K |
| Investing Cash Flow | -58.63K | -10.00K | -199.99K | 0.00 | -109.97K | 812.32K |
| Financing Cash Flow | 1.30M | 814.66K | 602.57K | 908.24K | 1.15M | 620.01K |
Lexston Life Sciences Corp. Technical Analysis
Neutral
0.10
Price Trends
0.08
Negative
0.11
Negative
0.14
Negative
Market Momentum
>-0.01
Negative
48.79
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LEXT, the sentiment is Neutral. The current price of 0.1 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.08, and below the 200-day MA of 0.14, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.79 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:LEXT.
Lexston Life Sciences Corp. Peers Comparison
UnderperformOutperform
Sector (61)
TSE:LEXT
Lexston Life Sciences Corp.
0.07
-0.18
-72.00%
TSE:LSD.H
Lightspeed Discoveries
0.03
0.00
0.00%
TSE:LCR
NeonMind Biosciences Inc
0.03
0.02
200.00%
Lexston Life Sciences Corp. Corporate Events
Business Operations and Strategy
Lexston Mining Begins Phase 1 Exploration at Nevada’s Garfield Hills Property
Positive
Feb 2, 2026
Lexston Mining Corporation has engaged Geophasic Exploration LLC to launch Phase 1 of its exploration program at the Garfield Hills property in Mineral County, Nevada, where crews are set to mobilize on February 3, 2026. The work will center on so...
Business Operations and Strategy
Lexston Mining Grants Stock Options to Align Management With Exploration Strategy
Positive
Jan 26, 2026
Lexston Mining Corporation has granted incentive stock options to directors, officers and consultants to purchase up to 625,000 common shares at an exercise price of $0.095 per share, exercisable over five years. The options, which are subject to ...
Business Operations and StrategyPrivate Placements and Financing
Lexston Mining Raises $500,000 in Fully Subscribed Private Placement
Positive
Jan 20, 2026
Lexston Mining Corporation has closed a fully subscribed non-brokered private placement, raising $500,000 through the issuance of 6,250,000 units at $0.08 per unit, each consisting of one common share and a five-year warrant exercisable at $0.10. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.